BIOR Biora Therapeutics (NASDAQ) $0.22 intraday 24 Mar 2026: oversold bounce with heavy volume

We see BIOR stock trading at $0.22 on NASDAQ in the United States on 24 Mar 2026, with a surge in volume that fits an oversold bounce pattern. Volume is 169,446 versus an average of 60,809, giving a relative volume of 2.79. The intraday price band is tight at $0.22 low and high, while the one-year range is $0.15–$0.38. We examine why this small-cap biotech could offer a short-term bounce trade and what risks limit upside.

BIOR stock intraday snapshot

Price is $0.22 on NASDAQ in USD with 169,446 shares traded so far and average volume 60,809. Market cap reads $994,994 and shares outstanding are 4,522,700. Reported EPS is 0.36 and trailing PE shows 0.61, though reported metrics reflect accounting distortions in this profile.

Why an oversold bounce setup now

We flag the setup because volume is 2.79x the average while price sits near the lower half of its year range. Stocks that stage oversold bounces often show a large intraday volume spike and compressed price action, both visible here. Short-term traders typically target a reversion toward the 50-day average of $0.22, then the year high near $0.38 if momentum returns.

Fundamentals and downside risks

Biora Therapeutics, Inc. operates in Healthcare Biotechnology and carries severe balance-sheet strains: cash per share $9.64, book value per share -64.30, and net income per share -78.69. Current ratio is 0.30, signaling liquidity pressure. These metrics increase crash risk and mean any bounce should be treated as tactical, not a sign of durable turnaround.

Meyka AI rates BIOR with a score out of 100 and technical outlook

Meyka AI rates BIOR with a score out of 100: 64.88 | Grade B | HOLD. This grade factors S&P 500 comparison, sector and industry performance, financial growth, key metrics, forecasts, analyst consensus, and fundamental growth. Meyka AI’s forecast model projects a monthly price of $0.22 versus the current $0.22, implying 0.00% near-term change; forecasts are model-based projections and not guarantees.

Price targets, upside and downside scenarios

Conservative near-term price target: $0.25 (implied upside +13.64%). Optimistic target aligned to the one-year high: $0.38 (implied upside +72.73%). Downside reference: $0.15 (implied downside -31.82%). We set a tactical stop near $0.17 to limit losses for momentum trades.

Trading strategy and risk controls for an oversold bounce

We recommend a small, defined-size position for an intraday or short-term swing given low liquidity and high volatility. Enter on confirmed volume and a 15–30 minute price stabilization above $0.22. Place stop-loss at $0.17 and scale targets at $0.25 and $0.38. Watch bid-ask spreads and be ready to exit quickly.

Final Thoughts

Key takeaway: BIOR stock at $0.22 on NASDAQ shows a classic oversold bounce setup driven by 169,446 shares traded and relative volume 2.79. Fundamentals remain weak—negative book value and a low current ratio—so any bounce looks tactical. Meyka AI’s forecast model projects $0.22 monthly, matching the current price and implying 0.00% near-term change; forecasts are model-based and not guarantees. For traders we outline conservative upside to $0.25 and optimistic upside to $0.38, with a stop near $0.17. We use this as a short-duration, high-risk trade idea in the Biotechnology sector for United States investors in USD, not a long-term buy recommendation. For more data and live signals see our internal BIOR page and monitor news links for catalyst updates.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.